jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

May. 25, 2022

Jan. 22, 2024

jRCT2031220092

A single-dose study of HP-6050

A single-dose study of HP-6050

Inakura Hiroshi

Hisamitsu Pharmaceutical Co., Inc.

2-4-1 Marunouchi, Chiyoda-ku, Tokyo

+81-3-5293-1734

shikenjoho@hisamitsu.co.jp

Clinical Development Department Contact for Clinical Trial Information

Hisamitsu Pharmaceutical Co., Inc.

2-4-1 Marunouchi, Chiyoda-ku, Tokyo

+81-3-5293-1734

shikenjoho@hisamitsu.co.jp

Complete

May. 27, 2022

May. 31, 2022
16

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

- Healthy Japanese adult males and females aged >=18 and <40 years
- Body mass index (BMI) is >=18.5 and <25.0

- Subjects with vagal tone
- Subjects with current or history of serious cardiac, vascular, renal, hepatic, psychiatric/neurological, or metabolic diseases
- Subjects who received any drug within a week prior to application of the study drug

18age old over
40age old not

Both

Healthy adult

Single dose of HP-6050

Pharmacokinetic parameters, adverse events

Pharmacodynamics

Hisamitsu Pharmaceutical Co., Inc.
Review Board of Human Rights and Ethics for Clinical Studies
2-2-1, Kyobashi, Chuo-ku, Tokyo

+81-3-5213-0028

crb@hurecs.org
Approval

May. 27, 2022

No

none

History of Changes

No Publication date
5 Jan. 22, 2024 (this page) Changes
4 Mar. 14, 2023 Detail Changes
3 Aug. 18, 2022 Detail Changes
2 June. 10, 2022 Detail Changes
1 May. 25, 2022 Detail